Details for: STELARA
Company: JANSSEN INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02459671 | STELARA | USTEKINUMAB | 5 MG / ML | SOLUTION | INTRAVENOUS |
| 02320673 | STELARA | USTEKINUMAB | 45 MG / 0.5 ML | SOLUTION | SUBCUTANEOUS |
| 02320681 | STELARA | USTEKINUMAB | 90 MG / 1.0 ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - STELARA (ustekinumab) - Serious Skin Disorders (Exfoliative Dermatitis and Erythrodermic Psoriasis)
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - STELARA (ustekinumab) - Serious Skin Disorders (Exfoliative Dermatitis and Erythrodermic Psoriasis)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.